PRAME and hematologic disorder: Importantly, our data suggest that PRAME may be a broad, multi-cancer immunotherapy target in pediatric extracranial solid malignancies, similar to efforts in hematologic malignancies where clinical trials are underway (e.g., NCT02494167 and NCT02203903).